Hormonal
Tirzepatide significantly improves all major lipid profile markers (HDL-C, LDL-C, Total Cholesterol, and Triglycerides) in a dose-dependent manner across patients with type 2 diabetes and obesity.
If you have type 2 diabetes or obesity, Tirzepatide (5mg, 10mg, or 15mg) significantly improves your cholesterol and triglyceride levels in a dose-dependent way. It raises 'good' HDL cholesterol and lowers 'bad' LDL cholesterol and triglycerides more effectively than placebo, and potentially better than other GLP-1 drugs. The benefits increase with higher doses (up to 15mg) over treatment periods of 27-72 weeks. Be aware of injection site reactions and high costs, but the metabolic improvements are robust.
The pooled analysis showed that tirzepatide was efficacious at improving all lipid markers, including cholesterol and triglycerides. Moreover, a clear dose response trend was visible across results from groups taking 5, 10, and 15 mg of tirzepatide.
Why this rating
Systematic review and meta-analysis of 13 randomized controlled trials (RCTs) with 14 articles.
Source
The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Muhammad Umar Mahar et al. · Journal of Obesity & Metabolic Syndrome · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →